Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179950
Title: | External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry |
Author: | Jimenez Fonseca, Paula Carmona Bayonas, Alberto Martínez Torron, Alba Alsina, Maria Custodio, Ana Serra, Olbia Cacho Lavín, Diego Limon Miron, Maria Luisa Sauri, Tamara López, Flora Visa, Laura Granja, Mónica Martínez Lago, Nieves Arrazubi, Virginia Vidal Tocino, Rosario Hernandez, Raquel Aguado, Gemma Cano, Juana María Martín Carnicero, Alfonso Mangas-Izquierdo, Montserrat Pimentel, Paola Fernández Montes, Ana Macias Declara, Ismael Longo, Federico Ramchandani, Avinash Martín Richard, Marta Hurtado, Alicia Azkarate, Aitor Hernández Pérez, Carolina Serrano, Raquel Gallego, Javier On Behalf Of The Agamenon-seom Study Group |
Keywords: | Càncer d'estómac Quimioteràpia Stomach cancer Chemotherapy |
Issue Date: | 1-Jan-2021 |
Publisher: | SAGE Publications |
Abstract: | Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. Methods: 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. Results: The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1-21.0) versus ToGA regimens (7.5, 6.4-8.5), p < 0.001. Patients with HER2-IHC 3+ cancers had higher response rates than those with IHC 2+/FISH+, odds-ratio 1.97 (95% CI, 1.25-3.09). The results achieved with CAPOX-trastuzumab were comparable to those attained with ToGA regimens. FOLFOX-trastuzumab was superior to ToGA schemes in terms of overall survival (OS), with a greater magnitude of effect in IHC 2+/FISH+ tumors (HR 0.47, 0.24-0.92) compared with IHC 3+ (HR 0.69, 0.49-0.96), and in diffuse (HR 0.37, 0.20-0.69) versus intestinal-type tumors (HR 0.76, 0.54-1.06). Conclusion: We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials. |
Note: | Reproducció del document publicat a: https://doi.org/10.1177/17588359211019672 |
It is part of: | Therapeutic Advances in Medical Oncology, 2021, vol. 13, p. 175883592110196 |
URI: | http://hdl.handle.net/2445/179950 |
Related resource: | https://doi.org/10.1177/17588359211019672 |
ISSN: | 1758-8359 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
17588359211019672.pdf | 903.97 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License